Thrombin-activated human platelets release substance(s) of a prote-ic nature which induce an increase in the intracellular calcium concentration in polymorphonuclear leukocytes (PMN). Aim of this study was to characterize the platelet released product(s) responsible for PMN stimulation.
PMN-stimulating activity was isolated from platelet supernatant by FPLC and HPLC. The N-terminal sequence analysis revealed that the purified fractions consisted in 90% of a peptide of 73 amino acids and in 10% of a peptide of 74 amino acids; both are truncated forms of the connective tissue-activating peptide III (CTAP-III), a platelet a-granule product, and have 3 and 4 additional amino acids at the N-terminus compared with the neutrophil-activating peptide 2 (NAP-2): Asp-Leu-Tyr and Ser-Asp-Leu-Tyr, respectively. Treatment of platelet supernatant (previously depleted of PMN-activating nucleotides) with Affi-gel heparin resulted in the disappearance of PMN-stimulating effects, suggesting that NAP-2 variants, which are heparin-binding proteins, account for ATP-independent PMN-stimulating activity of the supernatant. Cross-desensitization between rNAP-2 and the platelet supernatant and inhibition by the anti-NAP-2 antibody are in agreement with this conclusion. Although NAP-2 and its variants are reportedly generated from the inactive precursors, CTAP-III and platelet basic protein, through a proteolytic cleavage, NAP-2 variants were not generated in our system by proteases deriving from platelets or contaminating leukocytes. Indeed, treatment of intact platelet suspensions with different protease inhibitors failed to modify the calcium stimulating activity of the resulting supernatants. In conclusion, thrombin-activated platelets release NAP-2 variants which are not generated outside the platelets by proteolytic processing but are released in an active form. This finding enhances our understanding of platelet-PMN interaction in thrombosis and inflammation.
References
1
Henson PM.
Interactions between neutrophils and platelets. Lab Invest 1990; 62: 391-393
3
Cerletti C,
Evangelista V,
Molino M,
Piccardoni P,
Maugeri N,
de Gaetano G.
Polymorphonuclear leukocytes modulate platelet function. In: The role of platelets in blood-biomaterial interactions
Missirlis YF,
Wautier J-L.
eds. Kluwer Academic Publishers; Dordrecht: 1993: 95-106
4
Cerletti C,
Evangelista V,
Molino M,
de Gaetano G.
Platelet activation by polymorphonuclear leukocyte: role of cathepsin G and P-selectin. Thromb Haemost 1995; 74: 213-217
6
Takahashi A,
Yamamoto K,
Okuma M,
Sasada M.
Transient calcium elevation in polymorphonuclear leukocytes triggered by thrombin-activated platelets. Eur J Haematol 1992; 48: 196-201
9
Del Maschio A,
Corvazier E,
Maillet F,
Kazatchkine MD,
Maclouf J.
Platelet-dependent induction and amplification of polymorphonuclear leucocyte lysosomal enzyme release. Br J Haematol 1989; 72: 329-335
10
Walz A,
Dewald B,
Baggiolini M.
Formation and biological activity of NAP-2, a neutrophil-activating peptide derived from platelet alpha-granule precursors. In: Molecular and cellular biology of cytokines
Oppenheim JJ,
Powanda MC,
Kluger MJ,
Dinarello CA.
eds. Wiley-Liss, New York: 1990: 363-368
11
Car BD,
Baggiolini M,
Walz A.
Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases. Biochem J 1991; 275: 581-584
12
Miller MD,
Krangel MS.
Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992; 12 (1,2) 17-46
13
Walz A,
Dewald B,
von Tschamer V,
Baggiolini M.
Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III, and platelet factor 4 on human neutrophils. J Exp Med 1989; 170: 1745-1750
14
Walz A,
Baggiolini M.
A novel cleavage product of β-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils. Biochem Biophys Res Commun 1989; 159: 969-975
15
Cohen AB,
Stevens MD,
Miller EJ,
Atkinson MAL,
Mullenbach G.
Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets. Am J Physiol 1992; 263: L249-L256
17
Lindley I,
Aschauer H,
Seifert J-M,
Lam C,
Brunowsky W,
Kownatzki E,
Thelen M,
Peveri P,
Dewald B,
von Tscharner V,
Walz A,
Baggiolini M.
Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc Natl Acad Sci USA 1988; 85: 9199-9203
18
Maugeri N,
Evangelista V,
Celardo A,
Dell’Elba G,
Martelli N,
Piccardoni P,
de Gaetano G,
Cerletti C.
Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. Thromb Haemost 1994; 72: 450-456
19
Berman CL,
Yeo EL,
Wencel-Drake JD,
Furie BC,
Ginsberg MH,
Furie B.
A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. J Clin Invest 1986; 78: 130-137
20
Kuhns DB,
Wright DG,
Nath J,
Kaplan SS,
Basford RE.
ATP induces transient elevations of [Ca2+]i in human neutrophils and primes these cells for enhanced O2- generation. Lab Invest 1988; 58: 448-453
22
Moser B,
Schumacher C,
von Tscharner V,
Clark-Lewis I,
Baggiolini M.
Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 1991; 266: 10666-10671
23
Yan Z,
Zhang J,
Holt JC,
Stewart GJ,
Niewiarowski S,
Poncz M.
Structural requirements of platelet chemokines for neutrophil activation. Blood 1994; 84: 2329-2339
24
Holt JC,
Harris ME,
Holt AM,
Lange E,
Henschen A,
Niewiarowski S.
Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and β-thromboglobulin. Biochemistry 1986; 25: 1988-1996
25
Brandt E,
Van Damme J,
Flad H-D.
Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III. Cytokines 1991; 3: 311-321
26
Holt JC,
Niewiarowski S.
Conversion of low-affinity platelet factor 4 to p-thromboglobulin by plasmin and trypsin. Biochim Biophys Acta 1980; 632: 284-289
27
Walz A,
Baggiolini M.
Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J Exp Med 1990; 171: 449-454
29
Yan Z,
Holt JC,
Stewart GJ,
Niewiarowski S.
Neutrophil-activating inter-crine secreted by porcine platelets is active without proteolytic processing. Am J Physiol 1993; 265: C1396-C1404
30
Rucinski B,
Poggi A,
James P,
Holt JC,
Niewiarowski S.
Purification of two heparin-binding proteins from porcine platelets and their homology with human secreted platelet proteins. Blood 1983; 61: 1072-1080
31
Hirsh PD,
Hillis LD,
Campbell WB,
Firth BG,
Willerson JT.
Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-691
33
Reilly IAG,
Doran JB,
Smith B,
Fitzgerald GA.
Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986; 73: 1300-1309
34
Stewart ME,
Douglas JT,
Lowe GDO,
Prentice CRM,
Forbes CD.
Prognostic value of beta-thromboglobulin in patients with transient cerebral ischae-mia. Lancet 1983; 2: 479-482
37
Carry M,
Korley V,
Willerson JT,
Weigelt L,
Ford-Hutchinson AW,
Tagari P.
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-236
38
Heffner JE,
Sahn SA,
Repine JE.
The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders?. Am Rev Respir Dis 1987; 135: 482-492
